

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 February 2024 (22.02.2024)



(10) International Publication Number
WO 2024/036372 A1

(51) International Patent Classification:

A61K 51/08 (2006.01) A61K 47/12 (2006.01)
A61K 9/08 (2006.01) A61P 35/00 (2006.01)
A61K 47/10 (2017.01)

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/AU2023/050776

(22) International Filing Date:

16 August 2023 (16.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2022902326 16 August 2022 (16.08.2022) AU

(71) Applicant: **CLARITY PHARMACEUTICALS LIMITED** [AU/AU]; National Innovation Centre, 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU).

(72) Inventors: **MCINNES, Lachlan Eion**; C/- Clarity Pharmaceuticals Limited, National Innovation Centre, 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU).
IRONSIDE, Michael David; C/- Clarity Pharmaceuticals Limited, National Innovation Centre, 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU).

(74) Agent: **DAVIES COLLISON CAVE PTY LTD**; Level 15, 1 Nicholson Street, Melbourne, Victoria, Show / Hide columns, Victoria 3000 (AU).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING AND USE THEREOF IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES



(I)

(57) Abstract: The present invention relates to formulations of radiolabelled compounds that are of use in radiotherapy and diagnostic imaging. Specifically, the present invention relates to aqueous formulations of ⁶⁷Cu radiolabelled compounds of Formula (I) further comprising a buffer, gentisic acid, ethanol and ascorbic acid for use in radiotherapy and diagnostic imaging.

WO 2024/036372 A1